|
| Tuesday, 12 June 2012, 10:00 HKT/SGT | |
| |  | |
Source: A*STAR | |
|
|
|
SINGAPORE, June 12, 2012 - (ACN Newswire) - A team of scientists from A*STAR's Institute of Medical Biology (IMB) and Genome Institute of Singapore (GIS) together with clinicians from Boston's Brigham and Women's Hospital (BWH) have identified a unique set of cells in the cervix that are the cause of human papillomaviruses (HPV) related cervical cancers. Significantly, the team also showed that these cells do not regenerate when excised. These findings have immense clinical implications in the diagnosis, prevention and treatment of cervical cancer. The study was published in the prestigious journal, Proceedings of the National Academy of Sciences (PNAS), this week.
Cervical cancer is the 7th most common female cancer in Singapore and about 200 cases are diagnosed every year.[1] Infection with HPV is the most common cause or risk factor for cervical cancer. HPV infection causes pre-invasive cancer, termed CIN (Cervical Intraepithelial Neoplasia), which are pre-cancerous lesions that can progress and potentially become invasive cancer if left untreated.
Dr Christopher P. Crum, Director of Women's and Perinatal Pathology in the Department of pathology at BWH, said, "It has been a decades-old mystery why cervical cancers caused by HPV arise only from a discrete region of the cervix, known as the 'squamocolumnar junction', despite the presence of the virus throughout the genital tract. The discovery of these cells finally resolves this mystery and will have wide-ranging impact from developing more meaningful animal models of early cervical carcinogenesis to clinical implications."
The team discovered that this discrete set of cells, located at the squamocolumnar junction of the cervix, uniquely express biomarkers that are seen in all forms of invasive cervical cancers linked to HPV. This means that the signature markers of this population of cells can provide a way of distinguishing potentially dangerous precancerous lesions from those with a benign prognosis.
Dr Wa Xian, Principal Investigator at IMB, said, "Our study also revealed that this exotic population of cells does not reappear after ablation[2] by cone biopsy. This finding helps to explain the low rate of new HPV infections in the cervix after excisional therapy and also raises the distinct possibility that preemptive removal of these cells in young women could reduce their risk of cervical cancer. This could be an alternative to current vaccines which only protect against HPV 16 and 18."
This study further validates previous work[3] by Dr Xian and Dr McKeon in collaboration with BWH and NUS, which showed for the first time that some cancers originate from just a small set of cells that are unique from the other cells that reside around them. (Refer to Background)
Dr Frank Mckeon, Senior Group Leader at GIS, said, "Our previous work on esophageal cancer opened up the possibility of 'preventive therapy' to stamp out the disease by eliminating this small group of cells. This recent work in the cervix further validates this concept and raises important possibilities for early intervention to prevent malignancies linked to very small populations of these unusual, discrete population of cells."
Prof Birgitte Lane, Executive Director of IMB, said, "This compelling study lends further weight to the importance of specific target cell populations underlying cancer. It is a powerful example of what can be done by combining skilled pathology with modern molecular genetics to uncover important new information, even in such a well-studied disease as cervical cancer."
Prof Ng Huck Hui, Acting Executive Director of GIS, said, "This study is a fine example of how A*STAR research institutes can integrate our research capabilities to better collaborate with an international partner like the Brigham and Women's Hospital to carry out excellent research with strong clinical and translational applications."
Background
In a landmark paper published in Cell in June 2011, Dr Wa and Dr Mckeon identified a novel mechanism for the evolution of highly aggressive cancers in collaboration with BWH and NUS. They discovered that a discrete population of cells at the junction of the esophagus and stomach were linked to precursors of esophageal cancer (Barrett's metaplasia). It was the first time scientists realized that some cancers originate from just a small set of cells that are unique from the other cells that reside around them.
Notes for editor:
The research findings described in this news release can be found on the online Early Edition (EE), the week of 11th June 2012, of PNAS under the title "A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer", by Michael Herfsa,b, Yusuke Yamamotoc, Anna Lauryd, Xia Wange, Marisa R. Nuccia, Margaret E. McLaughlin-Drubinf, Karl Mungerf, Sarah Feldmangg, Frank D. McKeonc,e, Wa Xiana,h,1, and Christopher P. Crumaa,1.
[1] www.singhealth.com.sg/PatientCare/ConditionsAndTreatments/Pages/home.aspx - "Cervical Cancer"
[2] Cervical ablation is the removal of some of the outer layers of the cervix. Gynecologists perform cervical ablation when there is evidence or suspicion of cervical cancer.
[3] This paper can be found in the 24 June, 2011 advance online issue of Cell entitled "Residual Embryonic Cells as Precursors of a Barrett's-Like Metaplasia".
About the Genome Institute of Singapore (GIS)
The Genome Institute of Singapore (GIS) is an institute of the Agency for Science, Technology and Research (A*STAR). It has a global vision that seeks to use genomic sciences to improve public health and public prosperity. Established in 2001 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards the goal of individualized medicine. The key research areas at the GIS include Systems Biology, Stem Cell & Developmental Biology, Cancer Biology & Pharmacology, Human Genetics, Infectious Diseases, Genomic Technologies, and Computational & Mathematical Biology. The genomics infrastructure at the GIS is utilized to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact. www.gis.a-star.edu.sg
About the Institute of Medical Biology (IMB)
IMB is one of the Biomedical Sciences Institutes of the Agency for Science, Technology and Research (A*STAR). It was formed in 2007, the 7th and youngest of the BMRC Research Institutes, with a mission to study mechanisms of human disease in order to discover new and effective therapeutic strategies for improved quality of life. From 2011, IMB also hosts the inter-research institute Skin Biology Cluster platform. IMB has 20 research teams of international excellence in stem cells, genetic diseases, cancer and skin and epithelial biology, and works closely with clinical collaborators to target the challenging interface between basic science and clinical medicine. Its growing portfolio of strategic research topics is targeted at translational research on the mechanisms of human diseases, with a cell-to-tissue emphasis that can help identify new therapeutic strategies for disease amelioration, cure and eradication. For more information about IMB, please visit www.imb.a-star.edu.sg.
Contact:
Ong Siok Ming (Ms)
Senior Officer, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6826 6254
Email: ong_siok_ming@a-star.edu.sg
Topic: Research and development
Source: A*STAR
Sectors: Science & Research
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| A*STAR |
| Dec 6, 2022 14:00 HKT/SGT |
|
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| Sept 30, 2021 16:00 HKT/SGT |
|
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes |
| July 31, 2020 08:00 HKT/SGT |
|
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials |
| July 24, 2020 17:00 HKT/SGT |
|
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2 |
| Oct 22, 2019 04:00 HKT/SGT |
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
| June 28, 2019 08:00 HKT/SGT |
|
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms |
| Apr 5, 2019 18:00 HKT/SGT |
|
Passing of Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow |
| Jan 21, 2019 13:00 HKT/SGT |
|
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer |
| More news >> |
 |
|
|
|
